Franklin Resources Inc. Increases Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Franklin Resources Inc. lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,776,880 shares of the biopharmaceutical company's stock after purchasing an additional 23,594 shares during the quarter. Franklin Resources Inc. owned 1.67% of Intra-Cellular Therapies worth $148,405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ITCI. The Manufacturers Life Insurance Company raised its holdings in shares of Intra-Cellular Therapies by 1.3% during the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company's stock valued at $1,614,000 after purchasing an additional 283 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Intra-Cellular Therapies by 13.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company's stock worth $1,648,000 after purchasing an additional 2,622 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Intra-Cellular Therapies by 3.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company's stock worth $23,649,000 after purchasing an additional 11,104 shares during the period. Captrust Financial Advisors raised its stake in Intra-Cellular Therapies by 47.0% during the 3rd quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company's stock valued at $589,000 after buying an additional 2,572 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at $1,715,000. 92.33% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently commented on ITCI shares. Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Cantor Fitzgerald reissued a "neutral" rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday. Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Finally, Piper Sandler restated a "neutral" rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of "Hold" and an average target price of $106.23.

Intra-Cellular Therapies Stock Performance

ITCI stock remained flat at $131.87 during trading on Friday. The stock's fifty day moving average price is $129.62 and its two-hundred day moving average price is $101.43. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.